Alliance members participating in the survey for 2020 progress report


As of September 2019, the organizations listed below were members of the AMR Industry Alliance. Those marked with an asterisk (*) responded to part or all of the second AMR Industry Alliance survey on progress, conducted in 2019. Those marked with an obelisk (†) responded to part or all of the first AMR Industry Alliance survey on progress, conducted in 2017.

Biotechnology companies/SMEs 

Allecra Therapeutics, Germany

*†Aequor Inc., United States

*Agile Sciences, United States

*AiCuris Anti-infective Cures GmbH, Germany

*†Alaxia Pharma, France

*Amplyx, United States

*Antabio, France

*Antibiotic Adjuvant, United States

*BioVersys AG, Switzerland

*Bugworks Research, India

Cardeas Pharma, United States

*Combioxin, Switzerland

*Curza, United States

*†Da Volterra, France

Deinove, France

Destiny Pharma Ltd., United Kingdom

Eligo Bioscience, France

*†Entasis Therapeutics, United States

*Fedora Pharmaceuticals Inc., Canada

Fastinov, Portugal

*Forge Therapeutics, United States

*Meiji Seika Pharma Co., Japan

Helperby Therapeutics plc, United Kingdom

†iNtRON Biotechnology Inc., Korea

MaaT Pharma, France

Macrolide Pharmaceuticals Inc., United States

*Melinta Therapeutics Inc., United States

Microbion Corporation, United States

MicuRx Pharmaceuticals Inc., China and United States

*Moderna, United States

*Motif Bio, France

Mutabilis, France

†Nabriva Therapeutics AG, Austria


Northern Antibiotics Ltd., Finland

*†Nosopharm, France

*NovaBiotics, United Kingdom

†NovaDigm Therapeutics Inc., United States

OJBio Ltd., United Kingdom

*Paratek, United States

*†Peptilogics Inc., United States

Pherecydes Pharma, France

*Rebiotix, United States

*Scynexis, United States

*SetLance, Italy

*SinSa Labs, Sweden

*Soligenix, United States

*Spero Therapeutics LLC, United States

*Stochos Therapeutics, United States

*Summit Therapeutics, United Kingdom

Synthetic Genomics, United States

Sysmex, United Kingdom

TAXISpharma, United States

*†Tetraphase Pharmaceuticals, United States

*Venatorx Pharmaceuticals Inc., United States

VibioSphen, France

Vitas Pharma Ltd., India

*Xellia, Denmark




Large research-based biopharmaceutical companies 

*†AstraZeneca plc, United Kingdom

*Boehringer Ingelheim, Germany

*Evotec, Germany

*†F. Hoffmann-La Roche AG.

*†GlaxoSmithKline plc, United Kingdom

*†Johnson & Johnson, United States

*†Merck KGaA, Germany

*†MSD (known as Merck and Co., Inc. in the U.S. and Canada), United States

*†Otsuka, Japan

*†Pfizer Inc., United States

*†Sanofi S.A., France

*†Shionogi & Co. Ltd., Japan

*Sumitomo Dainippon Pharma, Japan


*Aurobindo, India

*†Centrient Pharmaceuticals, The Netherlands

*Cipla Ltd., India

*†Mylan, United Kingdom

*NGB Laboratories, India

*†Novartis AG1, Switzerland

*†Teva Pharmaceuticals, Ltd. Israel


*†BD, United States

*†bioM̩érieux SA, France

Cepheid, United States

*†Curetis AG, Germany

*HemoCue AB, Sweden

*Luminex B.V., The Netherlands

*MeMed, Israel

*Mobidiag Oy Ltd., Finland

*Momentum Bioscience Ltd., United Kingdom

*Nemis Technologies, Germany

*Qiagen, Germany

QuantuMDx Ltd., United Kingdom

Spectromics, United Kingdom

Industry Associations2 


Alliance of Biotech companies in Europe combating Anti-Microbial resistance (BEAM Alliance)

Antimicrobial Innovation Alliance (AIA)

Association Innovative Medicines, The Netherlands

Association of the British Pharmaceutical Industry (ABPI)

Biotechnology Innovation Organization (BIO)

British Generic Manufacturers Association (BGMA)

British In Vitro Diagnostics Association (BIVDA)

European Federation of Pharmaceutical Industries and Associations (EFPIA)

German Association of Research-Based Pharmaceutical Companies (VFA)

International Federation of Pharmaceutical Manufacturers & Association (IFPMA

Japan Pharmaceutical Manufacturers Association (JPMA)

Medicines for Europe

UK BioIndustry Association (BIA)


1 For the purposes of this report, and due to the predominant nature of its AMR-relevant business, where a sector breakdown is provided, data submitted by Novartis were included under the generics sector, rather than the large research-based biopharmaceutical sector.

2 Industry associations were not asked to participate in the survey, as it focuses specifically on company activity.